Wells Fargo analyst Cerena Chen initiated coverage of Metsera (MTSR) with an Overweight rating and $65 price target The company “stands out” in a “crowded” obesity landscape with assets that promise monthly dosing and competitive efficacy without tolerability tradeoffs, the analyst tells investors in a research note. Wells sees a good risk/reward at current levels, saying data over the next year will strengthen Metsera’s “differentiated profile.” The firm points out the company’s platform so far has delivered assets with 18- and 19-day half-lives.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera price target raised to $62 from $56 at Guggenheim
- Metsera obesity monotherapy data ‘looks competitive,’ says BofA
- Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
- Morning Movers: Warner Bros. Discovery climbs after plans to separate
- Metsera, Inc. Reports Positive Phase 1 Trial Results